By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on

Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 7,300+ Worldwide
Symbol: AMGN


Genesis Research and Development Corporation 

Phylos, Inc.  In 2000, Phylos entered into collaboration with Amgen to apply Phylos' PROfusion™ technology to rapidly identify high-affinity binding agents to potential therapeutic targets supplied by Amgen. Amgen will use the sequences and structural information gained through this collaboration for its internal drug discovery programs.

UCB, Inc.  Contract manufacturing of Abarelix peptide active ingredient

EPIX Pharmaceuticals, Inc. 

Dyax  Antibody phage display

Company News
Amgen (AMGN) Release: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 5/27/2016 6:34:37 AM
Amgen (AMGN) Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 5/27/2016 6:26:04 AM
Amgen (AMGN) Announces Early Tender Results Of Senior Notes Exchange Offers 5/26/2016 6:06:04 AM
Amgen (AMGN) Announces Pricing Terms Of Senior Notes Exchange Offers 5/26/2016 6:05:12 AM
Amgen (AMGN) Announces Voting Results Of Annual Meeting Of Stockholders 5/20/2016 7:02:30 AM
Amgen (AMGN) Highlights Data To Be Presented At 21st Congress Of The European Hematology Association 5/20/2016 6:48:47 AM
Amgen (AMGN) Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients 5/19/2016 7:27:09 AM
Amgen (AMGN) Researchers Discover Gene that Cuts Heart Attack Risk 5/19/2016 7:15:08 AM
Amgen (AMGN)'s Breakaway from Cancer Public Service Announcement Delivers Message That Education, Resources And Hope Are Essential In The Fight Against Cancer 5/18/2016 7:14:23 AM
3 Biotech Stocks Investors Should Pick Up in May 5/17/2016 7:09:10 AM